The transdermal pharmaceutical preparations for the treatment of Parkinsons disease contain a combination of at least two active substances selected from the following groups of active substances: dopamine agonists and L-dopa, monoamine oxidase inhibitors, anticholinergics, NMDA-receptor antagonists, sympathomimetics at least two of the said active substances being members of different active substance groups.
